GSK Launches Advanced Therapies for Gynaecological Cancers in India
Chennai: GSK has announced the availability of its advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, marking its commitment to addressing the unmet need for specialized treatments in cancer care. Gynaecological cancers, including endometrial and ovarian cancers, are among the most common cancers in women in India and are on the rise.
Precision Therapies for Gynaecological Cancers
Jemperli is India’s first and only approved PD-1 immunotherapy for the second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced endometrial cancer. Zejula is the only once-daily oral PARP inhibitor approved in India as first-line monotherapy maintenance for all biomarker types in advanced ovarian cancer.
Efficacy and Safety
The efficacy of Jemperli is based on scientific evidence from the GARNET trial, which demonstrated an objective response rate of 45.5% in patients with dMMR/MSI-H advanced or recurrent endometrial cancer. Zejula’s phase-3 PRIMA trial showed durable, long-term remission in women with newly diagnosed advanced ovarian cancer.
Patient Support Program
To empower patients to access these innovative therapies, GSK is introducing ‘Phoenix’, a Patient Support Program. Bhushan Akshikar, Managing Director, GSK India, said, “The launch of Jemperli and Zejula marks a pivotal moment for GSK in India, as we foray into oncology with a strong focus on innovation-led, high-impact therapies.”
Dr. Shalini Menon, EVP – Medical Affairs, GSK India, said, “Gynaecological cancers represent a growing public health challenge in India, especially among women above the age of 50, and those with obesity and metabolic syndrome.” The molecules launched are supported by robust global clinical evidence and approvals from over 40 countries, including the US, UK, and EU.
